AbbVie announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C viru infection in adults and… read more.
Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a leading chronic liver disease in China, yet primary care capacity remains limited. To address this, the first national Guidelines for Diagnosis… read more.
The American Gastroenterological Association (AGA) today announced the launch of Nigel, an artificial intelligence (AI)-powered virtual assistant developed exclusively for gastroenterology and hepatology. Built using AGA’s trusted clinical guidance and developed in collaboration… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a semaglutide injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis… read more.
NICE(UK): Seladelpar can be used, within its marketing authorisation, as an option to treat primary biliary cholangitis, including associated pruritus, in adults. It can be used: i) with… read more.
Pre-retrieval imaging is moving liver transplantation toward a more precise and less invasive era. A new evidence synthesis shows how ultrasound, computed tomography, and magnetic resonance imaging can… read more.
The MHRA has authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH). In patients with MASH, a protein called thyroid hormone receptor beta… read more.
Roche announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD). By… read more.
AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir), an oral… read more.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today… read more.
Ipsen announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL)… read more.
Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
